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A B S T R A C T  
Objective: To highlight the emergence of Tigecycline resistance among ESBL producer gram negative organisms. 
Patients and Methods: This cross-sectional study was conducted in Lahore College for Women University Lahore 
Pakistan from 1st October 2015 to 20th March 2016. A total of 360 isolates of gram-negative rods were selected and 
processed for identification of ESBL producers via double disc synergy technique. In total 100 isolates were identified as 
ESBL producing gram-negative rods (Escherichia coli, Klebsiella spp., Proteus spp. and Acinetobacter spp.) and were 
further processed for antimicrobial resistance testing against Tigecycline disks (30ug) via Kirby Bauer Disc Diffusion 
method. 
Results: Out of 360 identified gram-negative rods, 100 (27.7%) were ESBL producers. Among these total 46% samples 
were from male patients and 54% from female patients. A maximum number of ESBL producers were recovered from 
pus & wound samples (54%). The most common ESBL producer was Escherichia coli followed by Klebsiella spp., 
Proteus spp. and Acinetobacter spp. Overall susceptibility rate of Tigecycline was 54%. Tigecycline resistance was 
greatest for ESBL producing Acinetobacter (n=8), followed by Proteus (n=14), Escherichia coli (n=18) and Klebsiella 
(n=6) (p=0.004). 
Conclusion: Although tigecycline showed very good results against ESBL producers, emergence of Tigecycline 
resistant ESBL producers is an alarming situation. 
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I n t r o d u c t i o n  
 
Infections caused by gram-negative bacteria have 
continued to be a major problem, especially in 
hospitalized patients. These are responsible for serious 
bloodstream infections, respiratory tract, skin and skin 
structure infections. Carbapenemases are a major cause 
of carbapenem resistance in Enterobacteriaceae.1 
Extended-Spectrum Beta-Lactamases are mainly 
produced by the Enterobacteriaceae family (and non-
fermentative gram-negative organisms) and are capable 
of hydrolyzing extended-spectrum beta-lactam antibiotics 
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like cephalosporin, monobactam and penicillin.2,3 The 
efforts to treat multidrug-resistant (MDR) microorganisms 
are mainly focused on gram-positive bacteria, evident by 
the development of novel antimicrobial agents like 
linezolid.4  Infections caused by MDR gram-negative bacilli 
have become a growing problem. Resistance to 
fluoroquinolones, co-trimoxazole and trimethoprim is 
frequently observed among ESBL producers, resulting in 
treatment failure and also greatly limiting the choice of 
antibiotics that can be used for treatment.5 
Carbapenems have been important drugs for the 
treatment of infections caused by ESBL producing E. coli 
and K. pneumoniae, however, carbapenem resistance is 
emerging in many areas of the world.6-8 Tetracycline 
derivative, Tigecycline has proved a remarkable drug, 
having in vitro activity against many of these MDR 
organisms.9 Tigecycline is the first in a new class of 
antibiotics, the glycylcyclines, licensed by the US Food 
and Drug Administration (FDA) in June 2005 for 
intravenous use in adults. Protein synthesis is ultimately 
inhibited, thereby exerting a bacteriostatic effect.10 
Tigecycline exhibits potent in vitro activity when tested 
against a broad spectrum of both tetracycline-susceptible 
and tetracycline-resistant gram-positive and gram-
negative bacteria. There is a lack of data on the treatment 
of severely ill patients from the pivotal trials with 
Tigecycline. Available data on the use of Tigecycline in 
severely ill patients are mostly from retrospective 
analyses of studies with a focus on identified pathogens 
rather than the clinical picture.11 This study aimed at 
determining the resistance rate of ESBL producing 
bacteria to Tigecycline. As the prevalence of ESBL-
producing bacteria is on the rise, newer choices of 
antibiotics for such organisms will help in treating critically 
ill patients infected by them. 
P a t i e n t s  a n d  M e t h o d s  
This cross-sectional study was conducted in Government 
College for Women under Lahore College for Women 
University Lahore Pakistan during the period of 1st 
October 2015 to 20th March 2016. Standard 
microbiological procedures like Gram staining, colony 
morphology, biochemical tests and Analytical Profile 
Index (API) were applied to differentiate the strains of 
gram-negative bacteria. Total 360 isolates of gram-
negative rods were selected from tertiary care hospital 
Lahore by using convenient sampling technique.   These 
isolates were processed for the identification of ESBL 
producers via Double disc synergy technique. Then ESBL 
producing gram-negative rods were further processed for 
antimicrobial resistance testing against Tigecycline disks 
(30ug) via Kirby Bauer Disc Diffusion method. Tigecycline 
susceptibility of different ESBL-producing gram-negative 
rods was compared by Pearson's chi-square. Their 
respective inhibition zone diameters were compared by 
ANOVA, keeping a value of p≤0.05 to be statistically 
significant.  
R e s u l t s  
Out of 360 identified gram-negative rods, 100 (27.7%) 
isolates were ESBL producers. Out of 100 ESBL 
producing gram-negative rods, 46% samples were from 
males and 54% from female patients. Regarding sample-
wise distribution, ESBL producers were most commonly 
found in pus & wound (54%), followed by urine samples 
(22%) (Figure 1). The most common ESBL producer was 
Escherichia coli 50% (n=50) followed by Klebsiella spp. 
20% (n=20), Proteus spp. 20% (20%) and Acinetobacter 
spp 10% (n=10). Overall susceptibility rate of tigecycline 
was 54% (Figure 2). 
 
Figure1: Sample wise isolation rate of ESBL 
producers. 
 
Figure 2: Overall Tigecycline resistance rate. 
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Figure 3: Organisms wise resistance pattern to 
Tigecycline. 
Tigecycline resistance rate was significantly different 
among four strains (p=0.004). Resistance was greatest 
for ESBL producing Acinetobacter (80% [n=8]), followed 
by Proteus ([70%] n=14), Escherichia coli (36%/ n=18) 
and Klebsiella (30%/n=6) (Figure 3). The mean clearance 
zone diameter was 19 ± 2 mm (95% CIs 18.4, 19.6). The 
four strains did not differ significantly in terms of mean 
inhibition zone diameters (p = 0.827) (Table 1). 
D i s c u s s i o n  
There are serious concerns regarding increasing trend of 
antimicrobial resistance among gram-negative bacteria as 
there has been little successful development of new 
antimicrobial agents targeting this group of organisms. 
Keeping in view this increasing burden of multi-drug 
resistant gram-negative rods and limited treatment 
options available, our study aimed to determine 
Tigecycline susceptibility in one major subgroup 
responsible for multi-drug resistance among gram-
negative rods, i.e. ESBL-producing gram-negative rods, to 
widen the treatment options available for treating 
infections with such organisms and to prevent treatment 
failure. In a recent report, the Infectious Diseases Society 
of America specifically addressed three categories of 
MDR gram-negative bacilli, namely, extended-spectrum 
cephalosporin-resistant E. coli and Klebsiella spp., MDR 
P. aeruginosa and carbapenem-resistant Acinetobacter 
spp.12 Contrary to what happened with gram-positive 
bacteria, no antibiotic from a new class has been 
developed specifically for MDR gram-negative bacilli. The 
glycylcyclines, Tigecycline is an exception, although was 
not developed specifically for the purpose of treating 
infections caused by such bacteria, this drug was found to  
have effective in-vitro activity against many of the MDR 
gram-negative bacilli.13 
 
In our study, 80% of the Acinetobacter strains were 
resistant to Tigecycline. This finding is slightly higher than 
observed by Navon-Venezia et al 6, reporting 78% of the 
multidrug-resistant A. baumannii isolates were resistant to 
Tigecycline. It is in complete agreement with Liu et al., a 
study that compared the in vitro activity of Tigecycline 
against 3,014 isolates of clinically important drug-resistant 
bacteria using disk diffusion methods, they included ESBL 
-producing E. coli (n = 602), K. pneumoniae (n = 736) and 
also A. baumannii (n = 726) that had been collected from 
patients, treated between 2008 and 2010 at 20 hospitals 
in Taiwan. They suggested Tigecycline resistance rate of 
30.1% in the disk diffusion testing method found among 
the ESBL-producing K. pneumoniae isolates.14 
In present study E. coli showed the highest rate of ESBL 
production which is similar to the study of Pallett and 
Hand15, in which it was concluded that CTX-M-producing 
E. coli often occurs in the community and E. coli is one of 
the commonest organisms causing urinary tract infections 
(UTIs) the choice of agents to treat these infections is 
diminishing. In the setting of infections by multi-drug 
resistant organisms like ESBL producers, Tigecycline 
remains our most reliable resort among all extended-
spectrum antimicrobials. Nandi et al reported out of 82 
E.coli, 14 (17.0%) were ESBL producers, none of them 
showed resistance to Tigecycline and out of 67 Klebsiella 
isolates, 21 (i.e 31.34%) were ESBL producers out of 
which only 1 (4.7%) was resistant to Tigecycline. Out of 
19 Acinetobacter spp isolated 3 (15.7%) were resistant to 
Tigecycline.16 Gill et al reported that 56.4% of the isolates 
were Escherichia coli, 28.2% were Klebsiella 
pneumoniae, 10.26% were Enterobacter species, and 
2.6% were each Klebsiella oxytoca and Acinetobacter 
species. ESBLs were found to be most sensitive to 
Table 1: Inhibition zone diameter of four strains 




Escherichia coli (mm) 19±2 0.274 
Klebsiella spp (mm) 19±1 
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tigecycline, intermediate in susceptibility to minocycline 
while least sensitive to doxycycline and tetracycline.17 
Khalid et al reported that out of 826 clinical isolates of 
Gram negative bacilli, 364 were ESBL producers. 
Escherichia coli was the most frequent ESBL producer 
followed by Klebsiella pneumoniae and Enterobacter spp. 
Carbapenems were found to be the most effective drug 
followed Tigecycline then Amikacin and Nitrofurantoin.18  
Naz et al reported 100% resistance in MβL positive 
isolates for Imipenem, Piperacillin + Tazobactum, 
Ceftriaxone, Co-amoxyclav, Cefoperazone+Sulbactam, 
Ciprofloxacin, and Amikacin, Doxycycline, and 
Gentamicin showed 91.2%, 94.0%, and 97.5% resistant 
rate respectively. No resistance was observed against 
Colistin.1  Although the research is going on in developing 
newer antimicrobial agents, yet their rate of development 
is quite slow.19 Hence, judicious use of antibiotics and 
appropriate antiseptic measures are the prime 
requirements in order to curtail the ever increasing 
resistance.19 The broad-spectrum antibiotics should be 
used empirically only in the serious infections and when 
the facility for susceptibility testing is not available.19 The 
authors further recommend a large scale in vivo study in 
order to establish the in vivo efficacy of Tigecycline 
against ESBL producing gram-negative rods. 
C o n c l u s i o n  
Although tigecycline showed very good results against 
ESBL producers, however, emergence of Tigecycline 
resistant ESBL producers is an alarming situation. 
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